Marvin R. Garovoy
Corporate Officer/Principal bei American Board of Internal Medicine
Aktive Positionen von Marvin R. Garovoy
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
American Board of Internal Medicine
American Board of Internal Medicine Miscellaneous Commercial ServicesCommercial Services The American Board of Internal Medicine operates as a self-appointed physician evaluation organization. The private company is based in Philadelphia, PA. The CEO of the company is Richard J. Baron. | Corporate Officer/Principal | - | - |
Karriereverlauf von Marvin R. Garovoy
Ehemalige bekannte Positionen von Marvin R. Garovoy
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
AEVI GENOMIC MEDICINE, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2012 | 31.12.2013 |
Arriva Pharmaceuticals, Inc.
Arriva Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Arriva Pharmaceuticals is a privately held biopharmaceutical company focused on developing anti-inflammatory therapies for treating respiratory diseases. The company's areas of therapeutic focus are: hereditary emphysema, Chronic Obstructive Pulmonary Disease (COPD) including smoking-related emphysema, cystic fibrosis and other respiratory indications. Arriva’s current clinical focus is the development of Respriva™, its nebulized, recombinant alpha 1-antitrypsin for hereditary emphysema. Arriva Pharmaceuticals, Inc., is located in Alameda, California. | Technik-/Wissenschafts-/F&E-Leiter | - | 19.01.2011 |
AceLink Therapeutics, Inc.
AceLink Therapeutics, Inc. BiotechnologyHealth Technology AceLink Therapeutics, Inc. is a biopharmaceutical startup founded in 2018 that focuses on developing safe and effective medicines to address genetic diseases with high unmet needs. AceLink Therapeutics is based in Newark, CA. The private company's initial focus is on developing novel therapeutics for Fabry disease and type 1 Gaucher disease. The company was founded in 2018 by Wen Chen, Marvin R. Garovoy, and Jerry Shen. Jerry Shen has been the CEO since 2018. | Gründer | 01.01.2018 | - |
AVID BIOSERVICES, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.09.2010 | - |
The University of California, San Francisco | Corporate Officer/Principal | - | - |
XOMA (US) LLC
XOMA (US) LLC Pharmaceuticals: MajorHealth Technology XOMA (US) LLC develops pharmaceutical preparations. It offers proprietary drugs and toiletries. The company is headquartered in Emeryville, CA. | Corporate Officer/Principal | - | - |
Ausbildung von Marvin R. Garovoy
New York University | Undergraduate Degree |
The State University of New York | Doctorate Degree |
Statistik
International
Vereinigte Staaten | 10 |
Operativ
Corporate Officer/Principal | 3 |
Chief Tech/Sci/R&D Officer | 3 |
Undergraduate Degree | 1 |
Sektoral
Health Technology | 6 |
Consumer Services | 4 |
Commercial Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
AVID BIOSERVICES, INC. | Health Technology |
Private Unternehmen | 5 |
---|---|
American Board of Internal Medicine
American Board of Internal Medicine Miscellaneous Commercial ServicesCommercial Services The American Board of Internal Medicine operates as a self-appointed physician evaluation organization. The private company is based in Philadelphia, PA. The CEO of the company is Richard J. Baron. | Commercial Services |
XOMA (US) LLC
XOMA (US) LLC Pharmaceuticals: MajorHealth Technology XOMA (US) LLC develops pharmaceutical preparations. It offers proprietary drugs and toiletries. The company is headquartered in Emeryville, CA. | Health Technology |
Arriva Pharmaceuticals, Inc.
Arriva Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Arriva Pharmaceuticals is a privately held biopharmaceutical company focused on developing anti-inflammatory therapies for treating respiratory diseases. The company's areas of therapeutic focus are: hereditary emphysema, Chronic Obstructive Pulmonary Disease (COPD) including smoking-related emphysema, cystic fibrosis and other respiratory indications. Arriva’s current clinical focus is the development of Respriva™, its nebulized, recombinant alpha 1-antitrypsin for hereditary emphysema. Arriva Pharmaceuticals, Inc., is located in Alameda, California. | Health Technology |
Aevi Genomic Medicine, Inc.
Aevi Genomic Medicine, Inc. Pharmaceuticals: MajorHealth Technology Aevi Genomic Medicine, Inc. is a clinical stage biopharmaceutical company, which engaged in the discovery of treatments for rare and orphan diseases. Its research and development efforts leverage an internal genomics platform and an ongoing collaboration with the Center for Applied Genomics (CAG) at The Children's Hospital of Philadelphia (CHOP). The company was founded by Andrew Leonard Pearlman on January 27, 2000 and is headquartered in Wayne, PA. | Health Technology |
AceLink Therapeutics, Inc.
AceLink Therapeutics, Inc. BiotechnologyHealth Technology AceLink Therapeutics, Inc. is a biopharmaceutical startup founded in 2018 that focuses on developing safe and effective medicines to address genetic diseases with high unmet needs. AceLink Therapeutics is based in Newark, CA. The private company's initial focus is on developing novel therapeutics for Fabry disease and type 1 Gaucher disease. The company was founded in 2018 by Wen Chen, Marvin R. Garovoy, and Jerry Shen. Jerry Shen has been the CEO since 2018. | Health Technology |
- Börse
- Insiders
- Marvin R. Garovoy
- Erfahrung